Day One Biopharmaceuticals, Inc. DAWN
Apr 24, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +131.01%
- 1 year
- +172.53%
- Market cap
- 2.22B
- Profit margin
- -55.98%
- YTD return
- +131.01%
- 1-year return
- +172.53%
- Open
- 21.53
- Previous close
- 21.53
- Day's range
- 21.53 – 21.53
2Y +6.10 (+39.53%)
Key statistics
- Enterprise value
- 2.03B
- PEG ratio
- 0.60
- Price / sales
- 0.00
- Price / book
- 5.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -15.82%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 5, 2026 | Mar 31, 2026 | -0.31 | -0.35 | -0.04 | -12.90% |
| Feb 24, 2026 | Dec 31, 2025 | -0.17 | -0.20 | -0.03 | -17.65% |
| Nov 4, 2025 | Sep 30, 2025 | -0.27839 | -0.19 | +0.09 | +31.75% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.29 | +0.06 | +17.14% |
| May 6, 2025 | Mar 31, 2025 | -0.46 | -0.35 | +0.11 | +23.91% |
| Feb 25, 2025 | Dec 31, 2024 | -0.35 | -0.69 | -0.34 | -97.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2026 | JP Morgan | down | Overweight | Neutral |
| Mar 10, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 9, 2026 | Wedbush | down | Outperform | Neutral |
| Mar 6, 2026 | Jones Trading | down | Buy | Hold |
| Mar 6, 2026 | Needham | down | Buy | Hold |
| Feb 25, 2026 | Wedbush | main | Outperform | Outperform |
About Day One Biopharmaceuticals, Inc.
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 181
- Website
- dayonebio.com
News
Crude Oil Jumps Over 12%; US Retail Sales Fall In January 
12 Health Care Stocks Moving In Friday's Intraday Session 
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday 
Nasdaq Down Over 300 Points; US Economy Loses 92,000 Jobs In February 
Earnings Scheduled For February 24, 2026 
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks - 12 Health Care Stocks Moving In Monday's Intraday Session
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - 12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on DAWN — it syncs with the Stock Master app.